

# Open and Transparent Pharmacometrics Publication Process

Marc R. Gastonguay, Ph.D., FISO P  
Matthew M. Riggs, Ph.D.

[marcg@metrumrg.com](mailto:marcg@metrumrg.com)

[mattr@metrumrg.com](mailto:mattr@metrumrg.com)


Metrum Research Group LLC



It's time for a fully open and transparent pharmacometrics manuscript review and publication process: Here's how it could work.  
#OpenScience



# Publication without Open Access



https://www.nature.com/articles/d41586-018-06178-7

nature.com > nature > news > article

a natureresearch journal

MENU ▾



Search E-alert Submit Login

News & Comment Research

News Opinion Research Analysis Careers Books & Culture

NEWS • 04 SEPTEMBER 2018


## Radical open-access plan could spell end to journal subscriptions


*Eleven research funders in Europe announce 'Plan S' to make all scientific works free to read as soon as they are published.*

Holly Else



# Current Open Access





<https://www.biorxiv.org/content/what-unrefereed-preprint>



Cold  
Spring  
Harbor  
Laboratory

bioRxiv

THE PREPRINT SERVER FOR BIOLOGY

[HOME](#) | [ABOUT](#) | [SUBMIT](#) | [ALERTS / RSS](#) | [CHANNELS](#)



[Advanced Search](#)

## What is an unrefereed preprint?

Before formal publication in a scholarly journal, scientific and medical articles are traditionally “peer reviewed.” In this process, the journal’s editors take advice from various experts—called “referees”—who have assessed the paper and may identify weaknesses in its assumptions, methods, and conclusions. Typically a journal will only publish an article once the editors are satisfied that the authors have addressed referees’ concerns.

Because this process can be lengthy, authors use the bioRxiv service to make their manuscripts available as “preprints” *before* peer review, allowing other scientists to see, discuss, and comment on the findings immediately. Readers should therefore be aware that articles on bioRxiv have not been finalized by authors, might contain errors, and report information that has not yet been accepted or endorsed in any way by the scientific or medical community.



[connect.biorxiv.org/relate/content/52](https://connect.biorxiv.org/relate/content/52)



**bioRxiv**  
beta  
THE PREPRINT SERVER FOR BIOLOGY

[HOME](#) | [ABOUT](#) | [SUBMIT](#) | [ALERTS / RSS](#) | [CHANNELS](#)

## Channel : Drug Development and Clinical Therapeutics

This channel curates preprints specific to quantitative methods in pre-clinical and clinical drug development, the approval and post-marketing phases, and clinical therapeutics. The papers can range in varying topics in this discipline:

- Clinical Pharmacology and Therapeutics (#cpt)
- Therapeutic Drug Monitoring (#tdm)
- Pharmacometrics (#phmx)
- Quantitative Systems Pharmacology (#qsp)
- Clinical Trial Design/Optimal Design (#ctd, #od)
- Pharmacoeconomics (#pec)
- Meta analyses (#metanal)

This list will grow over time. Please feel free to suggest new topics.

Instructions for authors ([click here to view/hide](#))



<https://www.biorxiv.org/content/early/2017/04/03/123240>



**bioRxiv**  
THE PREPRINT SERVER FOR BIOLOGY

[HOME](#) | [ABOUT](#) | [SUBMIT](#) | [ALERTS / RSS](#) | [CHANNELS](#)

Search



[Advanced Search](#)

New Results

## Practical Unidentifiability Of Receptor Density In Target Mediated Drug Disposition Models Can Lead To Over-Interpretation Of Drug Concentration Data

Andrew M Stein

doi: <https://doi.org/10.1101/123240>

This article is a preprint and has not been peer-reviewed [what does this mean?].

**Abstract**

[Info/History](#)

[Metrics](#)

[Supplementary material](#)

[Preview PDF](#)

[Previous](#)

[Next](#)

Posted April 3, 2017.

[Download PDF](#)

[Email](#)

[Supplementary material](#)

[Share](#)

[Citation Tools](#)

[Tweet](#)

[Like 0](#)

[G+](#)



# More Work to Be Done

